<?xml version="1.0" encoding="UTF-8"?>
<p>Beigel et al (2020) conducted a double-blind, randomized, placebo-controlled trial on intravenous remdesivir in patients with Covid-19. Patients were randomly divided into treatment and placebo groups receiving remdesivir for up to 10 days. The time of recovery in the patients who received remdesivir was shorter than that of the placebo group (ClinicalTrials.gov number: NCT04280705).
 <xref rid="cit0032" ref-type="bibr">32</xref>
</p>
